Connect with us

Business

One-shot COVID-19 vaccine may give Johnson & Johnson an edge – New York Post

Less may be more when it comes to rolling out a coronavirus vaccine. Johnson & Johnson’s one-dose vaccine could have an edge over Pfizer and Moderna’s shots– even…

Published

on

post featured image
ADVERTISEMENT

Less may be more when it comes to rolling out a coronavirus vaccine.
Johnson & Johnson’s one-dose vaccine could have an edge over Pfizer and Modernas shots– even though it’s still several weeks away from approval in the US, Wall Street analysts told The Post.
That’s because the single jabs will likely be easier to distribute across the country than its rivals two-dose regimens that are slowly going into Americans arms.
They are not that late, considering the fact that they are shooting for a one-dose…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Iowa Archbishop addresses the moral concerns of Johnson & Johnson vaccine – KCCI Des Moines
Article feature image
Okta CEO defends $6.5 billion deal for rival Auth0 after shares fall – CNBC
Article feature image
Stop Letting Google Get Away With It – Gizmodo